[1] SAEED M, WENDLAND M F, WATZINGER N. MR contrast media for myocardial viability,microvascular integrity and perfusion. 2000(3). doi:10.1016/S0720-048X(0)00198-4
[2] GERBER B L, LIMA J A C, GAROT J. Magnetic resonance imaging of myocardial infarct. 2000(6). doi:10.1097/00002142-200012000-00006
[3] ROGERS W J Jr, KRAMER C M, GESKIN G. Early contrast-enhanced MRI predicts late functional recovery after reperfused myocardial infarction. 1999(6)
[4] KIM R J, WU E, RAFAEL A. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. 2000(20). doi:10.1056/NEJM200011163432003
[5] BEEK A M, KUHL H P, BONDARENKO O. Delayed contrast enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction. 2003(5). doi:10.1016/S0735-1097(3)00835-0
[6] KIM R J, FIENO D S, PARRISH T B. Relationship of MRI delayed contrast enhancement to irreversible injury,infarct age,and contractile function. 1999(19)
[7] FIENO D S, KIM R J, CHEN E L. Contrast-enhanced magnetic resonance imaging of myocardium at risk:distinction between reversible and irreversible injury throughout infarct healing, 2000(6)
[8] KLEIN C, NEKOLLA S G, BENGEL F M. Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging.Comparison with positron emission tomography. 2002(2). doi:10.1161/hc0202.102123
[9] MAHRHOLDT H, WAGENER A, JUDD R M. Assessment of myocardial viability by cardiovascular magnetic resonance imaging. 2002(8). doi:10.1053/euhj.2001.3038
[10] WILSON J M, VILLAREAL R P, HARIHARAN R. Magnetic resonance imaging of myocardial fibrosis in hypertrophic cardiomyopathy. 2002(3)
[11] INGKANISORN W P, RHOADS K L, ALETRAS A H. Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction. 2004(12). doi:10.1016/j.jacc.2004.02.046
[12] INGKANISORN W P, RHOADS K L, KELLMAN P. MRI delayed hyperenhancement overestimates acute myocardial infarction size in humans, 2002(z2)
[13] CHOI S I, JIANG C Z, LIM K H. Application of breath-hold T2-weighted,first-pass perfusion and gadolinium-enhanced T1-weighted MR imaging for assessment of myocardial viability in a pig model. 2000(5). doi:10.1002/(SICI)1522-2586(200005)11:5<, 476::AID-JMRI2>, 3.0.CO, 2-5
[14] PETERSEN S E, VOIGTLANDER T, KREITNER K F. Late improvement of regional wall motion after the subacute phase of myocardial infarction treated by acute PTCA in a 6-month follow-up. 2003(3). doi:10.1081/JCMR-120022264
[15] GERBER B L, GAROT J, BLUEMKE D A. Accuracy of contrast-enhanced magnetic resonance imaging in predicting improvement of regional myocardial function in patient after acute myocardial infarction. 2002(9). doi:10.1161/01.CIR.0000027818.15792.1E
[16] OSHINSKI J N, YANG Z, JONES J R. Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging. 2001(23). doi:10.1161/hc4801.100351
[17] GREBE O, PAETSCH I, KESTLER H A. Optimal acquisition parameters for contrast enhanced magnetic resonance imaging after chronic myocardial infarction. 2003(4). doi:10.1081/JCMR-120025231
[18] AMADO L C, GERBER B L, GUPTA S N. Accurate and objective infarct sizing by contrast-enhanced magnetic resonance imaging in a canine myocardial infarction model, 2004(12)
[19] WAGNER A, MAHRHOLDT H, THOMSON L. Effects of time,dose,and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. 2006(10). doi:10.1016/j.jacc.2006.01.059
[20] BREMERICH J, SAEED M, ARHEDEN H. Normal and infarcted myocardium:differentiation with cellular uptake of manganese at MR imaging in a rat model, 2000(2)
[21] PISLARU S V, NI Y, PISLARU C. Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent. 1999(5) |
